1
|
Citi V, Barresi E, Piragine E, Spezzini J, Testai L, Da Settimo F, Martelli A, Taliani S, Calderone V. Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H 2S Donor Moiety, in Different Cancer Cell Lines. Int J Mol Sci 2023; 24:16131. [PMID: 38003321 PMCID: PMC10671447 DOI: 10.3390/ijms242216131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 10/30/2023] [Accepted: 11/01/2023] [Indexed: 11/26/2023] Open
Abstract
Metformin (Met) is the first-line therapy in type 2 diabetes mellitus but, in last few years, it has also been evaluated as anti-cancer agent. Several pathways, such as AMPK or PI3K/Akt/mTOR, are likely to be involved in the anti-cancer Met activity. In addition, hydrogen sulfide (H2S) and H2S donors have been described as anti-cancer agents affecting cell-cycle and inducing apoptosis. Among H2S donors, isothiocyanates are endowed with a further anti-cancer mechanism: the inhibition of the histone deacetylase enzymes. On this basis, a hybrid molecule (Met-ITC) obtained through the addition of an isothiocyanate moiety to the Met molecule was designed and its ability to release Met has been demonstrated. Met-ITC exhibited more efficacy and potency than Met in inhibiting cancer cells (AsPC-1, MIA PaCa-2, MCF-7) viability and it was less effective on non-tumorigenic cells (MCF 10-A). The ability of Met-ITC to release H2S has been recorded both in cell-free and in cancer cells assays. Finally, its ability to affect the cell cycle and to induce both early and late apoptosis has been demonstrated on the most sensitive cell line (MCF-7). These results confirmed that Met-ITC is a new hybrid molecule endowed with potential anti-cancer properties derived both from Met and H2S.
Collapse
Affiliation(s)
- Valentina Citi
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
| | - Elisabetta Barresi
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126 Pisa, Italy
| | - Eugenia Piragine
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
| | - Jacopo Spezzini
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
| | - Lara Testai
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126 Pisa, Italy
- Interdepartmental Research Center “Biology and Pathology of Ageing”, University of Pisa, 56126 Pisa, Italy
| | - Federico Da Settimo
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126 Pisa, Italy
| | - Alma Martelli
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126 Pisa, Italy
- Interdepartmental Research Center “Biology and Pathology of Ageing”, University of Pisa, 56126 Pisa, Italy
| | - Sabrina Taliani
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126 Pisa, Italy
| | - Vincenzo Calderone
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (V.C.); (E.B.); (E.P.); (J.S.); (L.T.); (F.D.S.); (S.T.); (V.C.)
- Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126 Pisa, Italy
- Interdepartmental Research Center “Biology and Pathology of Ageing”, University of Pisa, 56126 Pisa, Italy
| |
Collapse
|
2
|
Nayak SG, Poojary B, Kamat V, Puthran D. Novel thiazolidin‐4‐one clubbed thiophene derivatives via Gewald synthesis as anti‐tubercular and anti‐inflammatory agents. J CHIN CHEM SOC-TAIP 2021. [DOI: 10.1002/jccs.202000166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Boja Poojary
- Department of Chemistry Mangalore University Mangaluru Karnataka India
| | - Vinuta Kamat
- Department of Chemistry Mangalore University Mangaluru Karnataka India
| | - Divyaraj Puthran
- Department of Chemistry Mangalore University Mangaluru Karnataka India
- Solara Active Pharma Sciences, Ltd. New Mangalore Karnataka India
| |
Collapse
|
3
|
Calvo R, Le Tellier A, Nauser T, Rombach D, Nater D, Katayev D. Synthesis, Characterization, and Reactivity of a Hypervalent-Iodine-Based Nitrooxylating Reagent. Angew Chem Int Ed Engl 2020; 59:17162-17168. [PMID: 32530081 DOI: 10.1002/anie.202005720] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Indexed: 11/11/2022]
Abstract
Herein, the synthesis and characterization of a hypervalent-iodine-based reagent that enables a direct and selective nitrooxylation of enolizable C-H bonds to access a broad array of organic nitrate esters is reported. This compound is bench stable, easy-to-handle, and delivers the nitrooxy (-ONO2 ) group under mild reaction conditions. Activation of the reagent by Brønsted and Lewis acids was demonstrated in the synthesis of nitrooxylated β-keto esters, 1,3-diketones, and malonates, while its activity under photoredox catalysis was shown in the synthesis of nitrooxylated oxindoles. Detailed mechanistic studies including pulse radiolysis, Stern-Volmer quenching studies, and UV/Vis spectroelectrochemistry reveal a unique single-electron-transfer (SET)-induced concerted mechanistic pathway not reliant upon generation of the nitrate radical.
Collapse
Affiliation(s)
- Roxan Calvo
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH Zürich, Vladimir-Prelog-Weg 2, 8093, Zürich, Switzerland
| | - Antoine Le Tellier
- Department of Organic Chemistry, University of Geneva, Quai Ernest Ansermet 30, 1211, Geneva 4, Switzerland
| | - Thomas Nauser
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH Zürich, Vladimir-Prelog-Weg 2, 8093, Zürich, Switzerland
| | - David Rombach
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH Zürich, Vladimir-Prelog-Weg 2, 8093, Zürich, Switzerland
| | - Darryl Nater
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH Zürich, Vladimir-Prelog-Weg 2, 8093, Zürich, Switzerland
| | - Dmitry Katayev
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology ETH Zürich, Vladimir-Prelog-Weg 2, 8093, Zürich, Switzerland
| |
Collapse
|
4
|
Calvo R, Le Tellier A, Nauser T, Rombach D, Nater D, Katayev D. Synthese, Charakterisierung und Reaktivität eines Nitrooxylierungsreagenzes basierend auf einer hypervalenten Iodverbindung. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202005720] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Roxan Calvo
- Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology ETH Zürich Vladimir-Prelog-Weg 2 8093 Zürich Schweiz
| | - Antoine Le Tellier
- Department of Organic Chemistry University of Geneva Quai Ernest Ansermet 30 1211 Geneva 4 Schweiz
| | - Thomas Nauser
- Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology ETH Zürich Vladimir-Prelog-Weg 2 8093 Zürich Schweiz
| | - David Rombach
- Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology ETH Zürich Vladimir-Prelog-Weg 2 8093 Zürich Schweiz
| | - Darryl Nater
- Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology ETH Zürich Vladimir-Prelog-Weg 2 8093 Zürich Schweiz
| | - Dmitry Katayev
- Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology ETH Zürich Vladimir-Prelog-Weg 2 8093 Zürich Schweiz
| |
Collapse
|
5
|
Testai L, Citi V, Martelli A, Brogi S, Calderone V. Role of hydrogen sulfide in cardiovascular ageing. Pharmacol Res 2020; 160:105125. [PMID: 32783975 DOI: 10.1016/j.phrs.2020.105125] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 07/17/2020] [Accepted: 08/05/2020] [Indexed: 12/11/2022]
Abstract
Cardiovascular diseases are the main cause of morbidity and mortality in the Western society and ageing is a relevant non-modifiable risk factor. Morphological and functional alterations at endothelial level represent first events of ageing, inevitably followed by vascular dysfunction and consequent atherosclerosis that deeply influences cardiovascular health. Indeed, myocardial hypertrophy and fibrosis typically occur and contribute to compromise overall cardiac output. As regards the intracellular molecular mechanisms involved in the cardiovascular ageing, an intricate network is emerging, revealing a role for many mediators, including SIRT1/AMPK/PCG1α pathway, anti-oxidants factors (i.e. Nrf-2 and FOXOs) and pro-inflammatory cytokines. Thus, the search for pharmacological and non-pharmacological strategies that can promote a "healthy ageing", in order to slow down age-related machinery, are currently an exciting challenge for the biomedical research. Interestingly, hydrogen sulfide (H2S) has been recently recognized as a new player capable to influence intracellular machinery involved in ageing and then it is view as a potential target for preventing cardiovascular diseases. Therefore, this review is focused on the role of H2S in cardiovascular ageing, and on the evidence of the relationship between progressive decline in endogenous H2S levels and the onset of various cardiovascular age-related diseases.
Collapse
Affiliation(s)
- Lara Testai
- Department of Pharmacy, University of Pisa, via Bonanno, 6-56120, Pisa, Italy; Interdepartmental Research Centre of Ageing, Biology and Pathology, University of Pisa, 56120, Pisa, Italy; Interdepartmental Research Centre "Nutraceuticals and Food for Health (NUTRAFOOD)", University of Pisa, 56120, Pisa, Italy.
| | - Valentina Citi
- Department of Pharmacy, University of Pisa, via Bonanno, 6-56120, Pisa, Italy
| | - Alma Martelli
- Department of Pharmacy, University of Pisa, via Bonanno, 6-56120, Pisa, Italy; Interdepartmental Research Centre of Ageing, Biology and Pathology, University of Pisa, 56120, Pisa, Italy; Interdepartmental Research Centre "Nutraceuticals and Food for Health (NUTRAFOOD)", University of Pisa, 56120, Pisa, Italy
| | - Simone Brogi
- Department of Pharmacy, University of Pisa, via Bonanno, 6-56120, Pisa, Italy
| | - Vincenzo Calderone
- Department of Pharmacy, University of Pisa, via Bonanno, 6-56120, Pisa, Italy; Interdepartmental Research Centre of Ageing, Biology and Pathology, University of Pisa, 56120, Pisa, Italy; Interdepartmental Research Centre "Nutraceuticals and Food for Health (NUTRAFOOD)", University of Pisa, 56120, Pisa, Italy
| |
Collapse
|
6
|
Liu J, Huang Z, Ma W, Peng S, Li Y, Miranda KM, Tian J, Zhang Y. Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance. Eur J Med Chem 2019; 162:650-665. [PMID: 30481687 DOI: 10.1016/j.ejmech.2018.10.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 09/30/2018] [Accepted: 10/01/2018] [Indexed: 01/11/2023]
Abstract
Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.
Collapse
Affiliation(s)
- Jingchao Liu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, 210009, China
| | - Zhangjian Huang
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, 210009, China
| | - Wenhuan Ma
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, China
| | - Sixun Peng
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, 210009, China
| | - Yunman Li
- State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, China.
| | - Katrina M Miranda
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, 85721, United States.
| | - Jide Tian
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, United States
| | - Yihua Zhang
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, 210009, China.
| |
Collapse
|
7
|
Ulusoy Güzeldemirci N, Cimok S, Daş-Evcimen N, Sarikaya M. Synthesis and Aldose Reductase Inhibitory Effect of Some New Hydrazinecarbothioamides and 4-Thiazolidinones Bearing an Imidazo[2,1- b]Thiazole Moiety. Turk J Pharm Sci 2018; 16:1-7. [PMID: 32454687 DOI: 10.4274/tjps.05900] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2017] [Accepted: 11/30/2017] [Indexed: 12/22/2022]
Abstract
Objectives To synthesize and characterize 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-alkyl/arylhydrazinecarbothioamide and 3-alkyl/aryl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinone derivatives and evaluate them for their aldose reductase (AR) inhibitory effect. Materials and Methods 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-alkyl/arylhydrazinecarbothioamides (3a-f) and 3-alkyl/aryl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinones (4a-j) were synthesized from 2-[6-(4-bromophenyl)imidazo[2,1-b]thiazole-3-yl]acetohydrazide (2). Their structures were elucidated by elemental analyses and spectroscopic data. The synthesized compounds were tested for their ability to inhibit rat kidney AR. Results Among the synthesized compounds, 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-benzoylhydrazinecarbothioamide (3d) showed the best AR inhibitory activity. Conclusion The findings of this study indicate that the different derivatives of the compounds in this study may be considered interesting candidates for future research.
Collapse
Affiliation(s)
| | - Selin Cimok
- İstanbul University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, İstanbul, Turkey
| | - Net Daş-Evcimen
- Ankara University, Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey
| | - Mutlu Sarikaya
- Ankara University, Faculty of Pharmacy, Department of Biochemistry, Ankara, Turkey
| |
Collapse
|
8
|
Tratrat C, Haroun M, Paparisva A, Geronikaki A, Kamoutsis C, Ćirić A, Glamočlija J, Soković M, Fotakis C, Zoumpoulakis P, Bhunia SS, Saxena AK. Design, synthesis and biological evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]triazol-6(5 H )ones. Pharmacophore models for antifungal activity. ARAB J CHEM 2018. [DOI: 10.1016/j.arabjc.2016.06.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|
9
|
Ajani OO, Aderohunmu DV, Ikpo CO, Adedapo AE, Olanrewaju IO. Functionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine. Arch Pharm (Weinheim) 2016; 349:475-506. [PMID: 27213292 DOI: 10.1002/ardp.201500464] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 04/14/2016] [Accepted: 04/22/2016] [Indexed: 01/09/2023]
Abstract
Benzimidazole derivatives are crucial structural scaffolds found in diverse libraries of biologically active compounds which are therapeutically useful agents in drug discovery and medicinal research. They are structural isosteres of naturally occurring nucleotides, which allows them to interact with the biopolymers of living systems. Hence, there is a need to couple the latest information with the earlier documentations to understand the current status of the benzimidazole nucleus in medicinal chemistry research. This present work unveils the benzimidazole core as a multifunctional nucleus that serves as a resourceful tool of information for synthetic modifications of old existing candidates in order to tackle drug resistance bottlenecks in therapeutic medicine. This manuscript deals with the recent advances in the synthesis of benzimidazole derivatives, the widespread biological activities as well as pharmacokinetic reports. These present them as a toolbox for fighting infectious diseases and also make them excellent candidates for future drug design.
Collapse
Affiliation(s)
- Olayinka O Ajani
- Department of Chemistry, Covenant University, CST, Canaanland, Ota, Ogun State, Nigeria
| | - Damilola V Aderohunmu
- Department of Chemistry, Covenant University, CST, Canaanland, Ota, Ogun State, Nigeria
| | - Chinwe O Ikpo
- Department of Chemistry, University of the Western Cape, Bellville, Cape Town, South Africa
| | - Adebusayo E Adedapo
- Department of Chemistry, Covenant University, CST, Canaanland, Ota, Ogun State, Nigeria
| | | |
Collapse
|
10
|
Novel 4-Thiazolidinone Derivatives as Anti-Infective Agents: Synthesis, Characterization, and Antimicrobial Evaluation. Biochem Res Int 2016; 2016:8086762. [PMID: 26925267 PMCID: PMC4746384 DOI: 10.1155/2016/8086762] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 01/07/2016] [Accepted: 01/12/2016] [Indexed: 11/29/2022] Open
Abstract
A series of new 4-thiazolidinone derivatives was synthesized, characterized by spectral techniques, and screened for antimicrobial activity. All the compounds were evaluated against five Gram-positive bacteria, two Gram-negative bacteria, and two fungi, at concentrations of 50, 100, 200, 400, 800, and 1600 µg/mL, respectively. Minimum inhibitory concentrations of all the compounds were also determined and were found to be in the range of 100–400 µg/mL. All the compounds showed moderate-to-good antimicrobial activity. Compounds 4a [2-(4-fluoro-phenyl)-3-(4-methyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-thiazolidin-4-one] and 4e [3-(4,6-dimethyl-pyrimidin-2-yl)-2-(2-methoxy-phenyl)-thiazolidin-4-one] were the most potent compounds of the series, exhibiting marked antimicrobial activity against Pseudomonas fluorescens, Staphylococcus aureus, and the fungal strains. Thus, on the basis of results obtained, it may be concluded that synthesized compounds exhibit a broad spectrum of antimicrobial activity.
Collapse
|
11
|
Synthesis and blood glucose and lipid-lowering effects of benzothiazole-substituted benzenesulfonylurea derivatives. MONATSHEFTE FUR CHEMIE 2015. [DOI: 10.1007/s00706-015-1471-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications. Bioorg Med Chem 2015; 23:422-8. [PMID: 25577707 DOI: 10.1016/j.bmc.2014.12.043] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 12/12/2014] [Accepted: 12/17/2014] [Indexed: 11/23/2022]
Abstract
Although there is a significant effort in the discovery of effective therapies to contrast both the pathological endocrine and metabolic aspects of diabetes and the endothelial dysfunction associated with this disease, no hypoglycemic drug has been proven to defeat the cardiovascular complications associated with type II diabetes. The aim of this research was to design new compounds exhibiting a double profile of hypoglycemic agents/NO-donors. The synthesis of molecules obtained by the conjunction of NO-donor moieties with two oral insulin-secretagogue drugs (repaglinide and nateglinide) was reported. NO-mediated vasorelaxing effects of the synthesized compounds were evaluated by functional tests on isolated endothelium-denuded rat aortic rings. The most potent molecule (4) was tested to evaluate the hypoglycemic and the anti-ischemic cardioprotective activities. This study indicates that 4 should represent a new insulin-secretagogue/NO-donor prodrug with an enhanced cardiovascular activity, which may contrast the pathological aspects of diabetes and endowed of cardioprotective activity.
Collapse
|
13
|
Mascarello A, Silva Frederico MJ, Gomes Castro AJ, Mendes CP, Dutra MF, Woehl VM, Yunes RA, Mena Barreto Silva FR, Nunes RJ. Novel sulfonyl(thio)urea derivatives act efficiently both as insulin secretagogues and as insulinomimetic compounds. Eur J Med Chem 2014; 86:491-501. [DOI: 10.1016/j.ejmech.2014.09.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Revised: 09/02/2014] [Accepted: 09/03/2014] [Indexed: 10/24/2022]
|
14
|
Bhardwaj A, Kaur J, Wuest F, Knaus EE. Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of cardiovascular risks in diabetes? Expert Rev Cardiovasc Ther 2014; 12:533-6. [PMID: 24725228 DOI: 10.1586/14779072.2014.897227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Cardiovascular complications are frequently observed in diabetic patients and are mostly caused by endothelial dysfunction associated with a decline in biosynthesis of nitric oxide (NO). In response to this concern, a remarkable increase in the interest for development of NO-releasing hybrid drugs has been observed. The NO-donating entity was linked to known drugs with the belief that NO is a vasorelaxant and an inhibitor of platelet aggregation or reduces thrombotic events. Many of these NO-releasing hybrid drugs have shown significant improvement in cardiovascular safety. In this editorial the potential roles of NO-releasing drugs for the treatment of cardiovascular complications in diabetes will be discussed.
Collapse
Affiliation(s)
- Atul Bhardwaj
- Department of Oncology, University of Alberta, Edmonton, AB, T6G 1Z2, Canada
| | | | | | | |
Collapse
|
15
|
Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A, Saraf SK. 4-Thiazolidinones: The advances continue…. Eur J Med Chem 2014; 72:52-77. [DOI: 10.1016/j.ejmech.2013.11.017] [Citation(s) in RCA: 194] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Revised: 11/12/2013] [Accepted: 11/15/2013] [Indexed: 12/26/2022]
|
16
|
Martelli A, Testai L, Anzini M, Cappelli A, Di Capua A, Biava M, Poce G, Consalvi S, Giordani A, Caselli G, Rovati L, Ghelardini C, Patrignani P, Sautebin L, Breschi M, Calderone V. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction. Pharmacol Res 2013; 78:1-9. [DOI: 10.1016/j.phrs.2013.09.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Revised: 09/18/2013] [Accepted: 09/20/2013] [Indexed: 11/29/2022]
|
17
|
Kaur J, Bhardwaj A, Huang Z, Narang D, Chen TY, Plane F, Knaus EE. Synthesis and Biological Investigations of Nitric Oxide Releasing Nateglinide and Meglitinide Type II Antidiabetic Prodrugs: In-Vivo Antihyperglycemic Activities and Blood Pressure Lowering Studies. J Med Chem 2012; 55:7883-91. [DOI: 10.1021/jm300997w] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jatinder Kaur
- Faculty of Pharmacy and Pharmaceutical
Sciences, University of Alberta, Edmonton,
Alberta T6G 2E1, Canada
| | - Atul Bhardwaj
- Faculty of Pharmacy and Pharmaceutical
Sciences, University of Alberta, Edmonton,
Alberta T6G 2E1, Canada
| | - Zhangjian Huang
- Faculty of Pharmacy and Pharmaceutical
Sciences, University of Alberta, Edmonton,
Alberta T6G 2E1, Canada
| | - Deepak Narang
- Department of Pharmacology,
Faculty of Medicine, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
| | - Ting-Yueh Chen
- Department of Pharmacology,
Faculty of Medicine, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
| | - Frances Plane
- Department of Pharmacology,
Faculty of Medicine, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
| | - Edward E. Knaus
- Faculty of Pharmacy and Pharmaceutical
Sciences, University of Alberta, Edmonton,
Alberta T6G 2E1, Canada
| |
Collapse
|
18
|
Tamboli Y, Lazzarato L, Marini E, Guglielmo S, Novelli M, Beffy P, Masiello P, Fruttero R, Gasco A. Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. Bioorg Med Chem Lett 2012; 22:3810-5. [DOI: 10.1016/j.bmcl.2012.03.103] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Revised: 03/25/2012] [Accepted: 03/28/2012] [Indexed: 01/15/2023]
|
19
|
Rapposelli S. Novel adenosine 5'-triphosphate-sensitive potassium channel ligands: a patent overview (2005-2010). Expert Opin Ther Pat 2011; 21:355-79. [PMID: 21269236 DOI: 10.1517/13543776.2011.553601] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
INTRODUCTION ATP-sensitive potassium channels are important metabolic regulators that link cellular metabolism to excitability. Their wide distribution in various tissues and organs makes them significant and topical targets in a large number of diseases. AREAS COVERED This review summarizes the current understanding of the molecular biology and pharmacology of K(ATP) channels, and the pathological states that result from aberrant expression or function of these proteins. In particular, relevant research, patents and patent applications of the past 5 years are discussed. EXPERT OPINION The tissue-specific K(ATP) channel modulation reflects an early discovery stage in drug design. The wide distribution of K(ATP) channels lets us consider them as valid targets for several pathologies, but on other hand the ubiquitous nature is a relevant drawback in developing an effective therapy because of the onset of side effects related to the lack of selectivity. On this basis, further investigations on both the structures and the localization of each receptor subtype should be carried out either exploring the structure-activity relationship of the already existing K(ATP) ligands or developing new selective fluorescent probes. To date, this research area still strives to design new tissue-targeted ligands that could pave the way to the development of innovative and effective drugs for clinical use.
Collapse
Affiliation(s)
- Simona Rapposelli
- Dipartimento di Scienze Farmaceutiche - Università di Pisa, Via Bonanno, 6, 56126 Pisa, Italy.
| |
Collapse
|